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The efficacy of a topical formulation containing 2% micronized griseofulvin applied 3 times 
daily for 3 weeks was evaluated in patients with superficial dermatophytoses. A double-blind 
parallel study was designed to compare the formulation to a standard therapy (tolnaftate 1% 
cream) and a placebo ointment. One of the 3 preparations was assigned at random to a total 
of 52 subjects. Thirteen of 15 subjects treated with placebo ointment were judged to be 
treatment failures. Nine of 18 subjects treated with griseofulvin, and 9 of 19 subjects treated 
with tolnaftate, responded to treatment. Clinical response appeared to be related to the 
severity of the infection rather than to the anatomical location of the lesions. The results 
suggest that griseofulvin may be effective following topical application and demonstrate the 
usefulness of positive and negative controls when evaluating topical antifungal agents. 
It is commonly believed that griseofulvin is 
ineffective when used topically. The origin of this 
notion is difficult to identify since early reports of 
the efficacy [1 1 or the failure [2 I of various formula-
tions containing the compound were merely pass-
ing references to unpublished trials. Results from 
one study that suggested efficacy in the treatment 
of tinea pedis [3) are difficult to interpret. Three 
different griseofulvin formulations were tested 
against placebo, but the allocation of the treat-
ments did not appear to have been randomized and 
there was no indication that the trial was con-
ducted double blind. More recently, an ointment 
formulation has been reported to be effective [4) 
and two reviews suggest that topical administra-
tion of griseofulvin may be a useful method of 
therapy [5,6). However, references to clinical stud-
ies to support this conclusion were not provided. As 
Goldman stated [7 ], this route of administration 
remains in the area of experimental therapeutics. 
Therapeutic efficacy of a topical formulation of 
any drug depends upon the availability of the 
compound for absorption and its subsequent pene-
tration in sufficient concentrations to the site of 
action. As well, therapeutic activity must be as-
sessed in properly designed clinical trials utilizing 
appropriate disease entites and treatment must be 
of adequate frequency and duration. Early animal 
investigations revealed that topically applied gri-
seofulvin was effective in treating experimental 
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fungal infections (8 ], but the ambiguous results 
during trials in humans may have been responsible 
for focusing attention on the local factors which 
influence response. For example, availability of 
griseofulvin and subsequent skin penetration may 
not be the limiting factors to efficacy. With the 
development of suitably sensitive techniques for 
measuring small amounts of griseofulvin in human 
skin [9], it was possible to demonstrate that a 
single application of an ointment containing 2% 
micronized griseofulvin to healthy skin produced 
skin concentrations of the drug several times 
higher than those measured after oral administra-
tion (Riegelman S, Epstein W: personal communi-
cation). The following study was designed to evalu-
ate the efficacy of this formulation in the treat-
ment of superficial fungal infections of human 
skin. The efficacy of the prepartation was com-
pared under double-blind conditions with that of a 
placebo ointment and 1% tolnaftate cream. The 
results with the test preparation were evaluated 
with respect to those with the positive control 
(tolnaftate) and the negative control (placebo). 
MATERIALS AND METHODS 
Subjects were selected from adults attending Duke 
University Medical Center outpatient dermatology 
clinics. The purpose of the investigation and the double-
blind controlled nature of the trial were explained to each 
subject and informed consent was obtained. Patients 
with the following were excluded from the investigation: 
dermatophytosis involving the hair and scalp and/or 
nails; lesions with secondary bacterial infections; those 
who had used griseofulvin or tolnaftate preparations 
within three months of admission to the study. 
During the initial clinic visit the diagnosis of a new or 
recurrent superficial dermatophytosis was confirmed by 
microscopic examination of skin scrapings dissolved in 
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10% potassium hydroxide. Sabouraud's agar plates were 
inoculated with material from the lesions. Subjects were 
assigned an investigational number in the order of their 
admission to the trial and were treated for 3 weeks with 
one of the topical preparations. They were examined 
weekly for response to treatment. One week after comple-
tion of the treatment regime, the subjects were requested 
to return for a follow-up visit in order to repeat the KOH 
examination and culture of material from any remaining 
lesions or to determine whether a recurrence had occurred 
following apparently successful therapy. On the initial 
visit and at the completion of therapy, hemoglobin 
concentration, white blood cell count, urinalysis, concen-
trations of serum bilirubin, SGOT, and alkaline phos-
phatase were obtained. 
Patients received one of the three following medica-
tions according to a predetermined randomized treat-
ment schedule: micronized griseofulvin, 2% concentra-
tion in an ointment base; ointment base only; tolnaftate, 
1.0% concentration in a cream base (Supplied as Tinac-
tin, Schering Corporation). Preinvestigation comparisons 
of the three preparations showed that they were nearly 
identical in appearance, but that the ointment prepara-
tions were slightly more greasy in consistency than the 
tolnaftate cream. Patients were instructed to apply the 
medication to the infected areas daily for 3 weeks; twice 
during the daytime and at bedtime after bathing the 
infected areas. Investigational material for each subject 
was supplied in three 15-gm tubes and one tube of 
medication was dispensed at each visit. All labels iden-
tifying the contents had been removed and replaced by a 
plain label containing the patient's study number. 
Response to treatment was judged by the clinical 
response after 3 weeks of therapy and the results of the 
follow-up KOH exam and culture. In order to be cunoid-
ered a treatment success, a lesion must have cleared 
completely during the 3 treatment weeks, or have im-
proved markedly and be accompanied by a negative 
follow-up KOH exam and culture. Any other response, 
including recurrence at the follow-up visit. was consid-
ered to be a treatment failure. 
Before breaking the double-blind code at the end of the 
trial the clinical course of each individual patient was 
reviewed. It became apparent that the severity of the 
infections was variable from subject to subject. There-
fore, patients were classified as having "severe" infec-
tions at the time of admission to the study if their 
infections satisfied at least one of the following three 
description: (1) lesions covered by a thick horny scale 
that were persistent and/or chronic; (2) lesions with a 
marked local inflammatory response suggesting a local-
ized hypersensitivity reaction to the infecting microorga-
nism; and (3) lesions involving large surface areas of the 
body. The remainder of the patients whose lesions did not 
conform to these clinical descriptions were classified as 
4
'not severe." 
Standard chi square techniques were utilized to evalu-
ate homogeneity of the treatment groups and for compar-
ison of the results. A Fisher Exact Probability Test for 2 
x 2 contingency tables was used when small expected 
values were encountered. The results were considered to 
be due to chance if p was found to be greater than 0.05. 
RESULTS 
Fifty-seven patients, predominantly white males 
(only 8 were female and 4 non-white), ranging in 
age from 20 to 64 years, were admitted to the 
study. One patient was excluded because of a 
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combined yeast-fungal infection, 1 was lost from 
the investigation because of admission to the 
hospital for elective surgery, and 3 moved away. Of 
the 5 subjects lost, 3 had received placebo, 1 
griseofulvin, and 1 tolnaftate. Three subjects were 
withdrawn from the investigation before the 3-
week period of treatment was concluded because of 
marked worsening of their infections and were 
considered to be treatment failures. Two of these 
were on placebo and the other tolnaftate. Two 
subjects who were treatment successes did not 
return for a follow-up visit 1 week after discontinu-
ing treatment. One had received griseofulvin and 
the other tolnaftate and both are included in the 
analysis of the results. All subjects except 2 re-
quired one tube of medication per week in order to 
treat their infection, and therefore the dose applied 
can be assumed to have been fairlv uniform for the 
majority of the subjects. In no- instances were 
adverse reactions to therapy encountered. 
Therefore, data from 52 patients was available 
for analysis. The clinical diagnosis was tinea pedis 
in 31 instances, tinea cruris in 10, tinea corporis in 
3, and tinea manuum in 2. In the remaining 6 
cases, the clinical diagnosis was that of a combined 
infection consisting of two of the above anatomical 
sites excluding feet. A higher proportion of griseo-
fulvin-treated patients had tinea pedis infections 
(Tab. I), but the difference was not statistically 
significant. 
Twenty-four subjects were classified as having 
infection of a "severe'' nature. The remaining 28 
had infections classified as "not severe." There was 
no difference in the distribution of severe cases 
among the treatment regimes (Tab. I). 
Potassium hydroxide preparations of skin scrap-
ings from the lesions were positive when examined 
by microscope for branching hyphae in all 52 cases 
on the admission visit. The initial cultures taken at 
this time were positive in 33 cases. yielded no 
growth in 13 cases, and were contaminated with 
overgrowth in 6 cases. The infecting microorga-
nisms were Trichophyton mentagrophytes (14 
cases), Trichophyton rubrum (12 cases), Epider-
mophyton floccosum (6 cases), and Trichophyton 
tonsurans (1 case). A mycologic diagnosis was 
made with greater frequency in subjects receiving 
tolnaftate (Tab. I). However, this difference was 
not significant at p < 0.05. 
Upon completion of the investigation, decoding 
revealed that 18 subjects had received griseofulvin, 
19 tolnaftate, and 15 placebo (Tab. II). Of the 21 
subjects classified as experiencing a beneficial 
response, 19 were given one of the two active 
preparations (9 received griseofulvin, 10 received 
tolnaftate). Only 2 subjects with a successful 
response received placebo. While each of the two 
active treatments proved to be significantly supe-
rior to placebo, no difference was observed between 
griseofulvin and tolnaftate. 
Twenty-four subjects were considered to have 
"severe" infections. Seven of these received griseo-
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TABLE I. The distribution of 52_ patients with superficial dermatophytoses with respect to treatment regime, 
anatomical site of infection, severity a{ infection, and mycologic diagnosis 
Treatment 
Griseofulvin Tolnaftate Placebo Chi square 
2'% ointment 1.0% cream ointment base (18 patients) (19 patients) (15 patients l 
Anatomical site Tinea pedis 
All other sites 
Classification of Severe 








a N .S. ~ not significant. 
TABLE II. The clinical-laboratory evaluation of the 
response to treatment in 52 patients with superficial 
dermatophytoses treated for 21 days with topical 










2%ointment 1.0~ cream ointment base 
Treatment success 9 10 2 
Treatment failures 9 9 13 
Totals 18 19' 15 
• Chi square for difference between the 3 treatments ~ 
p < 0.05. 
'Fisher exact probability test for griseofulvin versus 
tolnaftate: not significant. 
fulvin, 10 tolnaftate, and 7 placebo (Tab. III). 
While the number of subjects in each case is small, 
there would appear to be no differences between 
the treatments since the majority of "severe" cases 
treated resulted in a failure of therapy. For the 28 
subjects with a "not severe" infection, no differ-
ence was observed between the effectiveness of 
either griseofulvin or tolnaftate, and placebo was 
ineffective. Therefore, both active agents were 
effective in "not severe" cases but not very differ-
ent from placebo in "severe" cases. 
More than half of the patients treated had 
"athletes foot" (Tab. IV). Infections in this site 
were not more resistant to treatment than infec-
tions of other anatomical sites. 
Admission cultures were not diagnostic in 19 
subjects, usually because of failure of the dermato-
phyte to grown. The preponderance of mycologic 
diagnosis noted in the tolnaftate treatment group 
10 8 N.S." 
9 7 
lO 7 N.S." 
9 8 
16 8 0.10 > p > 0.05 
3 7 
TABLE Ill. The clinical-laboratory evaluation of the 
response to treatment in 52 patients classified as having 
severe and nat severe superficial dermatophytoses 
infections 
Treatment of 24 Treatment of28 
patients with patients with not 
severe infectionsa severe infections" 
Response Griseo- To!- Griseo- Tol-
fulvin naf- Placebo fulvin naf- Placebo 
2% tate ointment 2o/c tate ointment 
oint- 10% base oint- l.O'f base 
ment cream ment cream 
Treatment 1 3 1 8 7 I 
success 
Treatment 6 7 6 3 2 7 
failures 
Totals 7 10 7 11 9 8 
• Fisher exact probability test for griseofulvin versus 
tolnaftate: not significant. 
• Fisher exact probability test for griseofulvin versus 
tolnaftate: not significant. 
(Tab. I) is reflected in Table V as a higher 
proportion of patients treated successfully with 
tolnaftate. However, the total number of cases 
treated successfully with either griseofulvin or 
tolnaftate is similar. 
No relationship between medication and speed 
of response was apparent. When improvement 
occurred, it was evident within 1 week of institut-
ing therapy. 
A recurrence at the time of the follow-up visit 
occurred in only 1 patient in the trial. This subject 
received griseofulvin and was considered a treat-
ment failure. 
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TABLE IV. The response to treatment in 52 patients with 
superficial dematophytoses with respect to anatomical 
site of infection 
Griseoful- Tolnaf- Placebo 
vin 2.Mf tate LO% ointment Totals" 
ointment cream baae 
Sue- Fail- Sue- Fail- Sue· Fail- Sue- Fail-
cess ure cess ure cess ure cess ure 
Tinea pedis 7 6 5 5 1 7 13 18 
(13 patients) 








Totals 9 9 10 9 2 13 21 31 
• Chi square test on the total number of successes and 
failures in relation to the site of infection: not significant. 
TABLE V. The response to treatment in 52 patients with 
superficial dematophytoses with respect to mycologic 
diagnosis 
Treatment 
Griseoful- Tolnaf- Placebo 
"'in 2o/r tate lo/r ointment Totalgt~ 
ointment cream base 
Sue- Fail- Sue· Fail- Sue- Fail- Sue- Fail-
cess ure cess ure ce!is ure cess ure 
Admission 3 6 9 7 0 8 12 21 
culture 
positive 




Totals 9 9 10 9 2 13 21 31 
• Chi square test of the total number of successes and 
failures in relation to the result of the admission culture: 
not significant. 
DISCUSSION 
Random distribution of the patients to the three 
treatments resulted in groups that were similar 
with respect to sex and race and such local factors 
as severity of the infection and anatomical site of 
the infection. Both griseofulvin and tolnaftate were 
similar in effect and superior to placebo, independ-
ent of the site of infection. 
The criteria for stratifying patients as having 
"severe'" infection were based upon the considera-
tion that these cases, with justification, could have 
been treated systemically for a short period of time 
in conjunction with local therapy. Although the 
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classification may be criticized because it was 
undertaken after the investigation was completed 
rather than used for pretrial stratification, its 
usefulness for interpretation of the results is valid 
because it was carried out prior to decoding the 
treatments. The resistance of "severe" cases to the 
two active preparations (76% failure) suggests that 
failure was related to the severity of the lesion. The 
percentage of successes in the "not severe" group 
(75%) approaches that reported from investiga-
tions with other topical agents [10-13]. Therefore, 
under the conditions used in this study, the availa-
bility and subsequent penetration of griseofulvin 
and tolnaftate were adequate for treating some 
infections. 
The number of instances in which a pretreat-
ment mycologic diagnosis was made, while not 
statistically different, favored the tolnaftate treat-
ment. lt is not uncommon to experience difficulty 
in obtaining cultures from "ring worm" infections 
either because of failure of an organism to grow or 
due to a rapid overgrowth of contaminants. Since 
all patients had positive KOH preparations, it is 
unlikely that patients with nonspecific infections 
were included in the investigation. 
The results of this study indicate the value of 
including negative as well as positive controls when 
evaluating topical antifungal agents. The fre-
quency of success of both active preparations is 
much more meaningful when compared to the 
ineffectiveness of placebo treatment, particularly 
when relatively small numbers of cases are studied. 
In addition, the results suggest that trialists should 
consider prestratifying cases according to the se-
verity of the infection as well as other factors that 
are generally assumed to modify response. 
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